Summary of Alnylam Pharmaceuticals (ALNY) 2025 Conference Call Company Overview - **Company**: Alnylam Pharmaceuticals (ALNY) - **Event**: Bank of America Healthcare Conference - **Date**: May 14, 2025 Key Industry Insights - **Impact of Executive Orders**: The recent executive order regarding most favored nation pricing is still developing, making it difficult to assess its implications for Alnylam. However, the company benefits from having orphan drugs in the U.S., which may exempt them from future price negotiations under the IRA [3][4] - **Tariffs**: Current tariffs do not materially impact Alnylam's guidance, as the majority of their manufacturing is done in the U.S. through contract manufacturing organizations (CMOs) [8][9] Product Launch and Market Dynamics - **Cardiomyopathy Launch**: The launch of the cardiomyopathy product is a significant focus. Initial metrics show that 50% of health systems have completed the PNT process and are on formulary within five weeks of launch, which is faster than anticipated [18][19] - **Revenue Guidance**: Alnylam has guided for TTR revenue between $1.6 billion and $1.725 billion for the year, representing a 36% growth at the midpoint [23] - **Patient Access**: Approximately 70% of patients on the drug have zero out-of-pocket costs, primarily due to Medicare fee-for-service coverage [30] Competitive Landscape - **Market Size and Segmentation**: There are about 18,000 new patients initiating therapy annually, with a significant opportunity to increase diagnosis rates, currently at a 20% diagnosis rate [48] - **First-Line vs. Second-Line Treatment**: Alnylam is focused on first-line treatment due to the progressive nature of the disease and the need for effective early intervention [49] Patient and Physician Engagement - **Patient Compliance**: Alnylam has observed good compliance rates with their injectable therapies, which may be more effective than oral alternatives in ensuring patients receive the necessary treatment [58][60] - **Physician Awareness**: There is a good level of awareness among physicians regarding Alnylam's products, but further education is needed as the company expands its prescriber base [74] Future Outlook - **Revenue Reporting**: Alnylam will not be able to report revenue separately for Ambutra PN and Ambutra Centimeters due to them being the same product under one SKU [67] - **Market Positioning**: Alnylam is uniquely positioned to capture a broad patient base, including both hereditary and wild-type patients, due to its comprehensive label [72][73] Additional Considerations - **Direct-to-Consumer (DTC) Marketing**: Alnylam is engaging in targeted DTC marketing but is not heavily investing in broad campaigns like some competitors [65] - **Value-Based Agreements (VBAs)**: The company is extending its VBAs to ensure adherence and compliance, which is favorable for both patients and payers [60][61]

Core Viewpoint - Alnylam Pharmaceuticals reported better-than-expected financial results for Q1 2025, with adjusted losses narrower than estimates and significant revenue growth driven by strong product sales, particularly for Amvuttra [1][2][16]. Financial Performance - The company reported total revenues of $594.2 million, exceeding the Zacks Consensus Estimate of $588.2 million, and reflecting a 20% year-over-year increase [2]. - Net product revenues reached $468.5 million, up 28% year-over-year, primarily due to increased demand for Amvuttra, Givlaari, and Oxlumo [2][6]. - Net revenues from collaborators were $99.2 million, down 16% from the previous year, largely due to a prior milestone payment from Roche [3]. Product Sales - Amvuttra generated sales of $310 million, a 59% increase year-over-year, and surpassed estimates [6]. - Givlaari recorded sales of $67 million, a 15% increase year-over-year, but slightly missed estimates [7]. - Oxlumo's sales were $42.1 million, remaining flat year-over-year and missing estimates [7]. Expenses and Cash Position - Adjusted R&D expenses were approximately $241.3 million, remaining stable year-over-year [10]. - Adjusted SG&A expenses increased by 12% to $207 million, driven by marketing efforts for Amvuttra [11]. - Cash, cash equivalents, and marketable securities totaled $2.63 billion as of March 31, 2025, down from $2.69 billion at the end of 2024 [11]. Guidance and Collaborations - The company reiterated its 2025 financial guidance, expecting net product revenues between $2.05 billion and $2.25 billion, and collaboration revenues between $650 million and $750 million [12]. - Alnylam is advancing several collaborations, including with Regeneron and Roche, which are expected to enhance its product pipeline and revenue streams [13][14][17]. Market Performance - Year-to-date, Alnylam's stock has gained 8.4%, outperforming the industry, which has seen a decline of 1.8% [8].

Financial Performance - Alnylam's combined net product revenues reached $469 million, a 28% year-over-year (YoY) increase compared to Q1 2024[15, 25] - The U S TTR franchise primarily drove this growth, experiencing a 45% YoY increase[15] - The company is on track to meet its 2025 financial guidance, projecting combined net product revenues between $2050 million and $2250 million[15] - Non-GAAP operating income was $75 million, resulting in a 13% non-GAAP operating margin[70] Franchise Performance - The Rare Franchise achieved $109 million in global net product revenues in Q1 2025, representing an 8% YoY growth[28] - GIVLAARI sales increased by 15% YoY, driven by a ~15% increase in global patients on therapy[29] - The TTR Franchise experienced a robust 36% growth, primarily driven by U S performance, reaching $359 million in global net product revenues[30, 31] - U S TTR growth was 45% YoY, driven by demand (+32%), inventory (+6%), and gross-to-net adjustments (+7%)[32] AMVUTTRA Launch and Pipeline - AMVUTTRA captured approximately 70% of new hATTR-PN patient starts in the U S in Q1 2025[32, 35] - Alnylam is optimizing access pathways for AMVUTTRA in ATTR-CM at ~170 priority health systems, covering ~80% of Rx volume[39] - Regulatory approvals for AMVUTTRA have been granted in the U S and Brazil, with a positive CHMP opinion in the European Union[56]

Financial Data and Key Metrics Changes - In Q1 2025, Alnylam Pharmaceuticals reported total product revenues of $469 million, representing a 28% year-over-year growth, driven by a 36% increase in the TTR franchise revenues [8][40] - Collaboration revenue decreased by 16% to $99 million compared to the previous year, primarily due to a milestone achieved in Q1 2024 [41] - Non-GAAP operating profit for the quarter was $75 million, reflecting a $73 million improvement year-over-year [43] Business Line Data and Key Metrics Changes - The TTR franchise generated $359 million in global net revenues, a 36% increase compared to Q1 2024, with U.S. sales growing by 45% year-over-year [15][16] - The rare disease franchise, including GIVLAARI and OXLUMO, delivered $109 million in combined product sales, representing an 8% growth year-over-year [14] Market Data and Key Metrics Changes - In the U.S., the TTR franchise saw a 32% increase in demand driven by ongoing ONPATTRO patient uptake, with Ambutra capturing approximately 70% of new patient starts in Q1 2025 [16][19] - Internationally, the TTR franchise grew by 24% compared to Q1 2024, primarily due to increased demand for Ambutra [17] Company Strategy and Development Direction - Alnylam aims to become the global leader in TTR, focusing on broad access, driving awareness, and supporting treatment initiation for patients [7][10] - The company is committed to achieving sustainable non-GAAP profitability in 2025 and emphasizes a disciplined approach to capital allocation [9][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainties related to potential policy changes, including tariffs and FDA personnel reorganization, but expressed confidence in Alnylam's positioning to mitigate impacts [9][45] - The management reiterated guidance for continued growth and a strong launch in ATTR cardiomyopathy, projecting a robust 36% year-over-year growth in TTR franchise revenues [27][39] Other Important Information - Alnylam received FDA approval for Ambutra as the first and only silencer approved in the U.S. for ATTR Centimeters, with a successful launch underway [20][30] - The company is advancing its pipeline with several pivotal studies planned, including TRITON Centimeters and TRITON PN [47] Q&A Session Summary Question: Initial patients starting treatment and prescriber base - Management noted a broad uptake among both experienced and new prescribers, indicating strong early momentum in the cardiomyopathy launch [51][53] Question: Revenue benchmarks for ATTR cardiomyopathy - Management clarified that the revenue contribution from ATTR cardiomyopathy was not included in Q1 results, as the approval came late in the quarter [57][62] Question: Commercial strategies to capture market share - Management highlighted the unique mechanism of action of Ambutra and its potential as a first-line treatment, which is driving physician interest [64][66] Question: Use of Quick Start program and formulary access - Management reported limited use of the Quick Start program, with most patients paying zero copay, and confirmed no price difference between indications [70][72] Question: Impact of TrueBee on Ambutra's launch - Management indicated no headwinds from TrueBee's launch, emphasizing the growing and unsatisfied market for ATTR treatments [76][78] Question: Metrics on health systems and patient initiation - Management confirmed that over half of the 170 priority health systems have Ambutra on formulary, with many already initiating treatments [97][99]

Financial Data and Key Metrics Changes - In Q1 2025, Alnylam Pharmaceuticals reported total product revenues of $469 million, representing a 28% year-over-year growth, driven by a 36% increase in the TTR franchise revenues [6][37] - Collaboration revenue decreased by 16% to $99 million compared to the previous year, primarily due to a milestone achieved in Q1 2024 [38] - Gross margin on product sales remained at 85%, consistent with Q1 2024, but is expected to decrease for the remainder of the year due to escalating royalty rates [39][41] Business Line Data and Key Metrics Changes - The TTR franchise generated $359 million in global net revenues, a 36% increase year-over-year, with U.S. sales growing by 45% [14][15] - The rare disease franchise, including GIVLAARI and OXLUMO, delivered $109 million in combined product sales, reflecting an 8% growth year-over-year [13] - The TTR franchise's growth was primarily driven by increased demand for ONPATTRO and Ambutra, with a 32% increase in demand noted [15][16] Market Data and Key Metrics Changes - In the U.S., Ambutra captured approximately 70% of new patient starts in the first quarter of 2025, indicating strong market leadership despite new competition [18] - Internationally, the TTR franchise grew by 24% compared to the first quarter of 2024, driven by robust patient uptake [16] - The company noted that about 80% of the global addressable population remains untreated, presenting significant growth opportunities [19] Company Strategy and Development Direction - Alnylam aims to become the global leader in TTR, focusing on broad access, driving awareness, and supporting treatment initiation for patients [5][9] - The company is committed to achieving sustainable non-GAAP profitability in 2025 while continuing to advance its high-value pipeline [7][10] - Alnylam's strategy includes leveraging its innovative pipeline with multiple multibillion-dollar opportunities and maintaining strong financial performance through disciplined capital allocation [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning despite uncertainties related to potential policy changes, tariffs, and FDA reorganizations [7][8] - The management highlighted the strong early progress in the launch of Ambutra for ATTR cardiomyopathy and reiterated guidance for continued growth [6][37] - The company remains optimistic about achieving its 2025 goals, which include expanding access to its therapies and enhancing patient outcomes [10][26] Other Important Information - Alnylam received FDA approval for Ambutra as the first and only silencer approved in the U.S. for ATTR cardiomyopathy, with positive opinions from regulatory bodies in Brazil and the EU [20][29] - The company is advancing its pipeline with new clinical programs targeting various diseases, including a Phase I study for ALN434 targeting Type 2 diabetes [34][35] Q&A Session Summary Question: What is the profile of prescribers for Ambutra? - Management noted a broad uptake among both experienced prescribers and new doctors, indicating strong initial engagement with the product [48][51] Question: How does the revenue from ATTR cardiomyopathy compare to previous products? - Management clarified that the revenue from ATTR cardiomyopathy did not contribute to Q1 results, as the approval came late in the quarter [55][60] Question: What strategies are being employed to compete with tafamidis? - Management emphasized the unique mechanism of action of Ambutra and its compelling clinical data, which positions it as a first-line treatment option [62][64] Question: What are the dynamics of reimbursement for Ambutra? - Management explained that Ambutra has a single price across indications and highlighted the effectiveness of their patient support programs in facilitating access [68][70] Question: What are the expectations for formulary inclusion? - Management aims to complete formulary inclusion for all priority health systems by year-end, with encouraging early results already seen [81][82] Question: How is the early uptake of Ambutra characterized? - Management indicated that early uptake includes both switch patients and new patients, reflecting a strong initial market response [100][102]

Part I. Financial Information [Financial Statements (Unaudited)](index=6&type=section&id=ITEM%201.%20FINANCIAL%20STATEMENTS%20%28Unaudited%29) For the first quarter of 2025, Alnylam reported a **20% year-over-year increase** in total revenues to **$594.2 million**, driven by strong product sales, while recording a net loss of **$57.5 million**, an improvement from the **$65.9 million** loss in the same period last year, with total assets at **$4.21 billion** and sufficient capital to fund operations for at least the next 12 months [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance Sheet Summary (as of March 31, 2025) | Metric | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Total Current Assets** | $3,268,258 | $3,295,285 | | **Total Assets** | $4,213,811 | $4,239,983 | | **Total Current Liabilities** | $1,075,623 | $1,186,272 | | **Total Liabilities** | $4,098,376 | $4,172,895 | | **Total Stockholders' Equity** | $115,435 | $67,088 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statement of Operations Summary (Three Months Ended March 31) | Metric | 2025 (in thousands) | 2024 (in thousands) | Change | | :--- | :--- | :--- | :--- | | **Total Revenues** | $594,189 | $494,333 | +20.2% | | Net Product Revenues | $468,538 | $365,163 | +28.3% | | Net Revenues from Collaborations | $99,185 | $118,548 | -16.3% | | **Income (Loss) from Operations** | $18,077 | $(43,435) | N/A | | **Net Loss** | $(57,479) | $(65,935) | +12.8% | | **Net Loss per Share** | $(0.44) | $(0.52) | +15.4% | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary (Three Months Ended March 31) | Activity | 2025 (in thousands) | 2024 (in thousands) | | :--- | :--- | :--- | | Net cash used in operating activities | $(118,314) | $(81,515) | | Net cash provided by (used in) investing activities | $113,769 | $(67,620) | | Net cash provided by financing activities | $44,084 | $28,911 | [Notes to Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The company has six marketed products and generates revenue from four: AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO[24](index=24&type=chunk) - Based on the current operating plan, the company believes its cash, cash equivalents, and marketable securities as of March 31, 2025, are sufficient to fund operations for at least the next 12 months[29](index=29&type=chunk) Net Product Revenues by Product (Three Months Ended March 31) | Product | 2025 (in thousands) | 2024 (in thousands) | Change | | :--- | :--- | :--- | :--- | | **AMVUTTRA** | $309,992 | $195,241 | +59% | | **ONPATTRO** | $49,489 | $69,217 | -29% | | **GIVLAARI** | $66,968 | $58,056 | +15% | | **OXLUMO** | $42,089 | $42,649 | -1% | | **Total** | **$468,538** | **$365,163** | **+28%** | - Net revenues from collaborations decreased to **$99.2 million** in Q1 2025 from **$118.5 million** in Q1 2024, primarily because the 2024 period included a **$65.0 million** milestone payment from Roche, partially offset by a **$30.0 million** payment from Vir Biotechnology in Q1 2025[39](index=39&type=chunk)[53](index=53&type=chunk)[71](index=71&type=chunk) - The company is involved in patent infringement lawsuits against Pfizer/BioNTech and Moderna concerning their mRNA COVID-19 vaccines, and is also being sued by the University of Texas over its ONPATTRO product[96](index=96&type=chunk)[106](index=106&type=chunk)[108](index=108&type=chunk) [Management's Discussion and Analysis (MD&A)](index=25&type=section&id=ITEM%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) Management discusses the company's performance, highlighting a **28% increase** in net product revenues, driven by AMVUTTRA's **59% growth**, while advancing its late-stage pipeline and executing its Alnylam P⁵x25 strategy to achieve sustainable operating profitability by the end of 2025, despite a **7% rise** in operating expenses and a **14% increase** in SG&A due to marketing investments, maintaining a strong liquidity position with **$2.63 billion** in cash and marketable securities [Overview and Pipeline](index=25&type=section&id=Overview%20and%20Pipeline) - The company is executing its **"Alnylam P⁵x25" strategy**, aiming to become a top-tier biotech company by the end of 2025 with sustainable innovation and strong financial performance[118](index=118&type=chunk) - AMVUTTRA received FDA approval in March 2025 for the treatment of the cardiomyopathy of ATTR amyloidosis, a significant label expansion[119](index=119&type=chunk) - Key late-stage pipeline programs include zilebesiran (hypertension), nucresiran (ATTR amyloidosis), and mivelsiran (Alzheimer's disease and CAA)[126](index=126&type=chunk)[127](index=127&type=chunk) [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Revenue Breakdown (Three Months Ended March 31) | Revenue Type | 2025 (in thousands) | 2024 (in thousands) | % Change | | :--- | :--- | :--- | :--- | | Net product revenues | $468,538 | $365,163 | +28% | | Net revenues from collaborations | $99,185 | $118,548 | -16% | | Royalty revenue | $26,466 | $10,622 | +149% | | **Total Revenues** | **$594,189** | **$494,333** | **+20%** | - The **28% increase** in net product revenues was primarily driven by increased patient demand for AMVUTTRA, partially offset by a decrease in ONPATTRO sales due to patient switches to AMVUTTRA[158](index=158&type=chunk) - Collaboration revenue decreased mainly due to the recognition of a **$65.0 million** milestone from Roche in Q1 2024, partially offset by a **$30.0 million** payment from Vir and increased revenue from the Regeneron collaboration in Q1 2025[160](index=160&type=chunk)[164](index=164&type=chunk) - Royalty revenue increased **149%** due to higher global net sales of Leqvio by collaborator Novartis[160](index=160&type=chunk) - Selling, general and administrative (SG&A) expenses increased **14%** to **$239.9 million**, primarily due to increased marketing investment for TTR therapies and higher employee compensation[168](index=168&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) - Net cash used in operating activities was **$118.3 million** for the quarter, an increase from **$81.5 million** in the prior year period, mainly due to higher bonus payouts and interest payments[174](index=174&type=chunk)[175](index=175&type=chunk) - The company believes its cash, cash equivalents, and marketable securities as of March 31, 2025, are sufficient to meet its capital and operating needs for at least the next 12 months[180](index=180&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=ITEM%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) The company reports no significant changes in its financial market risk exposures, primarily related to interest rates, since December 31, 2024 - There have been no significant changes to the financial market risks described as of December 31, 2024[181](index=181&type=chunk) [Controls and Procedures](index=36&type=section&id=ITEM%204.%20CONTROLS%20AND%20PROCEDURES) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls over financial reporting during the quarter - The CEO and CFO concluded that disclosure controls and procedures were effective at a reasonable assurance level as of March 31, 2025[182](index=182&type=chunk) - No changes in internal control over financial reporting occurred during the quarter that have materially affected, or are reasonably likely to materially affect, internal controls[183](index=183&type=chunk) Part II. Other Information [Legal Proceedings](index=37&type=section&id=ITEM%201.%20LEGAL%20PROCEEDINGS) This section refers to Note 12 of the financial statements, which details the company's material pending legal proceedings, including patent infringement lawsuits filed by Alnylam against Pfizer and Moderna, and a lawsuit filed against Alnylam by the University of Texas - For a discussion of material pending legal proceedings, the report refers to Note 12, Commitments and Contingencies, in the financial statements[184](index=184&type=chunk) [Risk Factors](index=37&type=section&id=ITEM%201A.%20RISK%20FACTORS) The company outlines significant risks to its business, including a history of **$7.35 billion** in accumulated losses and the need for substantial funding, heavy dependence on third parties for collaborations and manufacturing, prominent industry risks such as potential clinical trial failures, regulatory hurdles, intense competition for products like AMVUTTRA, pricing pressures from regulations like the Inflation Reduction Act, and significant legal risks from ongoing patent litigation with Pfizer, Moderna, and the University of Texas - The company has a history of significant operating losses, with an accumulated deficit of **$7.35 billion** as of March 31, 2025[196](index=196&type=chunk) - The company relies on third parties for manufacturing and collaborations, and failure by collaborators like Roche, Novartis, or Sanofi to perform could delay or terminate product development and commercialization[189](index=189&type=chunk)[216](index=216&type=chunk)[221](index=221&type=chunk) - AMVUTTRA faces competition from Pfizer's VYNDAQEL/VYNDAMAX and BridgeBio's ATTRUBY for ATTR-CM, both of which are oral medications with lower list prices[366](index=366&type=chunk) - The Inflation Reduction Act (IRA) could negatively impact business, for example by requiring rebates if drug prices increase faster than inflation or by subjecting products to Medicare price negotiation[301](index=301&type=chunk) - The company is engaged in significant patent litigation, including lawsuits against Pfizer and Moderna for infringement related to their mRNA COVID-19 vaccines, and is being sued by the University of Texas over its ONPATTRO product[351](index=351&type=chunk)[354](index=354&type=chunk) - The company has **$1.04 billion** in convertible notes outstanding and may not have sufficient cash flow to service this indebtedness or repurchase the notes if required[384](index=384&type=chunk)

Core Viewpoint - Analysts forecast a quarterly loss of $0.56 per share for Alnylam Pharmaceuticals, indicating a significant year-over-year decline of 250%, while revenues are expected to increase by 19% to $588.18 million [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 4.6% in the past 30 days, reflecting a reassessment by covering analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are linked to short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Product revenues, net' at $464.60 million, representing a year-over-year increase of 27.2% [5]. - 'Revenues- Royalty revenue' is projected to reach $30.71 million, indicating a substantial year-over-year increase of 189.1% [5]. - 'Revenues- Net revenues from research collaborators' are expected to be $93.37 million, showing a decline of 21.2% year-over-year [5]. Product Revenue Estimates - 'Net Product Revenues- Oxlumo' is estimated at $44.67 million, reflecting a 4.7% increase from the prior year [6]. - 'Net Product Revenues- Givlaari' is projected to be $67.46 million, indicating a 16.2% increase from the previous year [6]. - 'Net Product Revenues- Amvuttra' is expected to reach $300.02 million, showing a significant year-over-year increase of 53.7% [6]. - 'Net Product Revenues- Onpattro' is estimated at $51.23 million, indicating a year-over-year decline of 26% [7]. Stock Performance - Alnylam shares have decreased by 5.6% over the past month, contrasting with the Zacks S&P 500 composite's decline of 0.8% [7].

Company Overview - Alnylam Pharmaceuticals (ALNY) is expected to report a year-over-year decline in earnings with a quarterly loss of $0.56 per share, reflecting a -250% change, while revenues are anticipated to be $587.72 million, an increase of 18.9% from the previous year [3][12]. Earnings Expectations - The consensus EPS estimate has been revised 5.17% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][10]. - The Earnings ESP for Alnylam is -12.28%, suggesting a lower Most Accurate Estimate compared to the Zacks Consensus Estimate, which complicates the prediction of an earnings beat [11][10]. Historical Performance - Alnylam has beaten consensus EPS estimates three times in the last four quarters, with a notable surprise of +128.57% in the last reported quarter [12][13]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, GSK is expected to report earnings of $1.08 per share, reflecting a -0.9% year-over-year change, with revenues projected at $9.54 billion, up 2.2% from the previous year [17]. - GSK's consensus EPS estimate has also been revised 1.9% lower, resulting in an Earnings ESP of -0.93%, making it difficult to predict an earnings beat [18].

Company Overview - Alnylam Pharmaceuticals (ALNY) shares increased by 8.5% to close at $243.27, following a notable trading volume, contrasting with a 6% loss over the past four weeks [1] - The company is expected to report a quarterly loss of $0.55 per share, reflecting a year-over-year decline of 243.8%, while revenues are projected to be $587.45 million, an increase of 18.8% from the previous year [2] Earnings Estimates - The consensus EPS estimate for Alnylam has been revised 1.5% lower in the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] - Alnylam holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Comparison - Alnylam is part of the Zacks Medical - Biomedical and Genetics industry, where Immunome, Inc. (IMNM) also operates, having seen an 11.7% increase in its stock price to $6.21, despite a -36.3% return over the past month [3] - Immunome's consensus EPS estimate has increased by 18.3% over the past month to -$0.67, representing a year-over-year change of -97.1%, and it also holds a Zacks Rank of 3 (Hold) [4]

Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering. In terms of deals, there have been 334 deals totaling US$107 billion in the siRNA gene silencing sector. The United States and Ireland stand out with two major M&A deals worth $54.9 billion. The highest deal volume was observed in 2023, while the highest deal value was seen in 2020. The slight decline in 2021, followed by a slight increase in 2022, may indic ...